Sentences with phrase «adoptive cell transfer»

A University of California at Los Angeles (UCLA) study headed by Antoni Ribas, M.D., Ph.D., is a first - in - human phase I clinical trial combining adoptive cell transfer of a T cell receptor engineered to recognize NY - ESO - 1 along with Yervoy ® (ipilimumab, anti-CTLA-4).

One approach would be to identify immune cells in a tumour, grow them in a lab, and then infuse them back into the patient — a technique called adoptive cell transfer.

Several trials of adoptive cell transfer techniques are currently under way for patients with pancreatic cancer, including:

Ma C., Fan R., Chodon T., Koya R.C., Wu Z., Ng C., Avramis E., Cochran A.J., Witte O.N., Baltimore D., Chmielowski B., Economou J.S., Anduix B.C., Ribas A., Heath J.R. Multifunctional T Cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy.

Immunologists and oncologists are harnessing the body's immune system to fight cancers and other diseases with adoptive cell transfer techniques.

CD8 + and CD8 − T cells were collected from either C57BL / 6 mice or adoptive cell transfer recipients one week after the rejection of BALB / c corneal allografts.

The «TGF beta» clinical trial, named for one of the elements that distinguish this approach, is part of an emerging class of immunotherapies that employ adoptive cell transfer.

The impact of Ex Vivo clinical grade activation protocols on human T - cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy.

Nicholas P Restifo, MD, National Cancer Institute, Center for Cancer Research, «Developing Curative Cancer Treatments Using Adoptive Cell Transfer - Based Immunotherapies»

However, adoptive cell transfer of TILs did mediate the objective complete response of 24 % of patients.

Researchers are also experimenting with another form of immunotherapy called adoptive cell transfer, which harvests and then reintroduces patients» tumor - infiltrating lymphocytes — cells with anti-tumor capabilities that dig deep behind enemy lines.

In the new research, Prins and Liau used a technique called adoptive cell transfer, which involves extracting and growing immune cells outside of the body, then reprogramming them with a gene known as New York Esophageal Squamous Cell Carcinoma, or NY - ESO - 1.

Nude mice were challenged with BALB / c corneal allografts one day after the adoptive cell transfers.

Another major avenue of immunotherapy for multiple myeloma is adoptive cell transfer.

«When evaluating the efficacy of either checkpoint blockade or adoptive cell transfer, one must consider the durability of clinical benefit,» they wrote.

Adding total body irradiation to preparative lymphodepletion chemotherapy prior to the adoptive cell transfer of tumor - infiltrating lymphocytes (TILs) had no effect on tumor regression in patients with metastatic melanoma, according to the results of a study published in the Journal of Clinical Oncology.

According to the study, previous research had shown that adoptive cell transfer was capable of mediating a durable tumor regression in patients with metastatic melanoma.

These treatments can be broken into 7 main categories: checkpoint inhibitors / immune modulators, therapeutic vaccines, adoptive cell transfer, monoclonal antibodies, oncolytic viruses, adjuvant immunotherapies, and cytokines.

Their three - year grant has enabled the team to investigate cancer immunotherapies, with a focus on checkpoint blockade and adoptive cell transfer, two of the most promising approaches to cancer immunotherapy.

These treatments can be broken into 4 main categories: checkpoint inhibitors / immune modulators, monoclonal antibodies, adoptive cell transfer, and oncolytic virus therapy.

Adoptive Cell Transfer (ACT) is a form of immunotherapy that targets tumors specifically and potently by utilizing large numbers of a patient's own immune cells to target and destroy cancer cells.

Adding total body irradiation to chemotherapy prior to the adoptive cell transfer of TILs had no effect on tumor regression in patients with metastatic melanoma.

Tactiva's lead platform is a unique approach to adoptive cell transfer (ACT), a form of immunotherapy in which a patient's own immune cells are drawn from blood, genetically engineered, multiplied and injected back into the patient in order to launch a powerful attack against cancer.